News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.
The company reported RMB133.9 million (US$20.5 million) for the quarter, up from RMB102.9 million in the same period of 2019.
The lab will perform DNA and RNA sequencing as well as well as liquid biopsy analyses to advance precision oncology in New Jersey and the East Coast.
The test leverages immune repertoire sequencing technology to identify individuals who have had a recent or prior SARS-CoV-2 infection.
On a call with investors this week, the firm described massive revenue increases and discussed how it plans to sustain and deploy these gains.
The Temple City, California-based firm delivered approximately 3.2 million billable tests in the quarter and recorded $295.0 million in revenues.
